Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ViraBloc is a proprietary, patent-pending elderberry (*Sambucus nigra*) extract developed by HerbalScience Group. Classified as a nutraceutical or dietary supplement rather than a pharmaceutical drug, it is marketed to support immune health and provide defense against viral infections, particularly influenza. The extract is produced using a specialized extraction technology designed to concentrate specific polyphenols and anthocyanins. Its primary mechanism of action involves inhibiting viral entry into host cells by blocking the attachment of viral particles to cell surfaces. ViraBloc has been commercialized in various formats, including lozenges, and has been featured in products such as New Chapter's "Blockade" and sold through retailers like GNC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ViraBloc.